---
title: "Longeveron | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 398 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286311858.md"
datetime: "2026-05-13T20:22:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286311858.md)
  - [en](https://longbridge.com/en/news/286311858.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286311858.md)
---

# Longeveron | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 398 K

Revenue: As of FY2026 Q1, the actual value is USD 398 K, beating the estimate of USD 323 K.

EPS: As of FY2026 Q1, the actual value is USD -0.19, missing the estimate of USD -0.1725.

EBIT: As of FY2026 Q1, the actual value is USD -4.814 M.

#### Revenues

Total revenues for Longeveron Inc. were $0.4 million for both the three months ended March 31, 2026, and March 31, 2025 . Clinical trial revenue increased by $0.1 million, or 46%, to $0.4 million in 2026, up from $0.3 million in 2025 . Contract manufacturing revenue decreased by $0.1 million, or 84%, to $20,000 in 2026, compared to $0.1 million in 2025 . Contract manufacturing lease revenue was $0 in 2026, down from $6,000 in 2025 .

#### Cost of Revenues and Gross Profit

Cost of revenues remained consistent at $0.1 million for both periods . Gross profit was $0.3 million for both the three months ended March 31, 2026, and March 31, 2025 .

#### Operating Expenses

General and administrative expenses decreased by $0.2 million, or 7%, to $2.7 million in 2026 from $2.9 million in 2025 . Research and development expenses decreased by $0.2 million, or 8%, to $2.3 million in 2026 from $2.5 million in 2025 . Total operating expenses were $5.039 million in 2026, compared to $5.456 million in 2025 .

#### Loss from Operations

Loss from operations improved to -$4.775 million in 2026 from -$5.181 million in 2025 .

#### Other Income

Other income, net, decreased by $0.2 million, or 77%, to $39,000 in 2026 from $0.2 million in 2025 .

#### Net Loss

Net loss decreased by $0.3 million, or 6%, to -$4.7 million in 2026 from -$5.0 million in 2025 . Basic and diluted net loss per share was -$0.19 in 2026, compared to -$0.34 in 2025 . Basic and diluted weighted average common shares outstanding were 24,786,282 in 2026, up from 14,950,734 in 2025 .

#### Balance Sheet Highlights

As of March 31, 2026, cash and cash equivalents were $15.8 million, compared to $4.7 million as of December 31, 2025 . Total assets increased to $21.210 million from $10.261 million . Total liabilities increased to $5.183 million from $4.586 million . Total stockholders’ equity increased to $16.027 million from $5.675 million .

#### Operational Metrics

Longeveron Inc. anticipates top-line results from the Phase 2b clinical trial for Hypoplastic Left Heart Syndrome (HLHS) in August 2026 . For Alzheimer’s disease (AD), the company had a positive Type B meeting with the FDA in March 2025 and is seeking strategic collaborations for a single Phase 2⁄3 clinical trial . The Investigational New Drug (IND) application for Pediatric Dilated Cardiomyopathy (PDCM) became effective in July 2025, with a Phase 2 clinical trial anticipated to start in 2027 . In March 2026, Longeveron Inc. completed a private placement of up to $30 million, with an initial $15 million funded .

#### Outlook / Guidance

Longeveron Inc. currently anticipates its existing cash and cash equivalents will fund operating expenses and capital expenditure requirements into the fourth quarter of 2026 . The company intends to pursue additional financing opportunities, capital raises, and non-dilutive funding options to support its operating plans . A partnering strategy is planned across development programs to accelerate market entry, increase capital efficiency, and leverage larger organizational resources .

### Related Stocks

- [LGVN.US](https://longbridge.com/en/quote/LGVN.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [TDK publishes 2026 annual report for fiscal year ended March 31, 2026](https://longbridge.com/en/news/287131408.md)
- [Royce Small-Cap Trust (NYSE: RVT) as of Apr 30, 2026 | RVT Stock News](https://longbridge.com/en/news/287103750.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)